Retatrutide tracker
Educational reference for Retatrutide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
144 h
Tmax
36 h
Category
glp1
Also known as: reta, LY3437943
> PLACEHOLDER — pending clinical review by licensed pharmacist. Retatrutide is an investigational triple agonist currently in phase 3 clinical development, targeting GLP-1, GIP, and glucagon receptors simultaneously. This multi-receptor engagement is hypothesised to produce additive or synergistic effects on energy balance, glucose metabolism, and body composition beyond what dual agonists achieve. Early-phase trials have shown substantial weight reduction and HbA1c improvement. With a half-life of approximately 144 hours and a Tmax of around 36 hours, it is designed for once-weekly subcutaneous administration. As an investigational compound, its long-term safety profile is still being characterised, making systematic side-effect and dose tracking especially important for early adopters enrolled in clinical protocols.
Mechanism
An investigational triple agonist targeting the GLP-1, GIP, and glucagon receptors. The added glucagon-receptor activity is hypothesized in research to increase energy expenditure alongside the incretin effects on appetite and glycemia.
Research summary
Investigational and not approved by the FDA. Phase 2 results for obesity and related conditions have been published; larger phase 3 evaluation is ongoing per the literature.
Dosing in the literature
Reported in early-phase trials as once-weekly subcutaneous administration under study protocols. There is no approved regimen; any specifics belong to the trial publications and prescribing clinicians, not this summary.
Reported side effects
Early trials report dose-dependent gastrointestinal effects and, consistent with glucagon activity, monitoring of heart rate and metabolic parameters. The full safety profile is not yet established given its investigational status.
Stacking notes
As an investigational compound, combination use is confined to study settings. General incretin considerations (GI tolerability, hypoglycemia when combined with glucose-lowering agents) are discussed in the literature.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Retatrutide phase 2 obesity trial (NEJM) · New England Journal of Medicine (2023)search PubMed/NEJM for retatrutide phase 2
- Retatrutide (LY3437943) clinical development reviews · peer-reviewed review articles (2023)investigational; not FDA-approved
References
- Retatrutide phase 2 trialDOI: 10.1056/NEJMoa2301972
Track Retatrutide in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.